Study design
This research project was conducted in Alicante General University Hospital, Alicante, Spain, between November 2019 and January 2021. This was a single centre, observational, non-randomized, retrospective, non-comparative study analysing the effectiveness and safety of erenumab and galcanezumab in the prevention of chronic or episodic migraine. The study was approved by the institutional Ethics Committee (EREGAL-MI) according to the STROBE checklist. All the patients enrolled in this study were asked for their informed consent.